JAMIA

Verana Health Research on Missing Data for Diabetic Retinopathy Severity Published in the Journal of the American Medical Informatics Association

Retrieved on: 
Tuesday, May 9, 2023
Science and technology in Asia, Electronic health record, Varnaq, Diabetes, IRIS, Registry, Diabetic retinopathy, American Medical Informatics Association, Missing data, Ophthalmology, Quality of life, American Academy, DR, American Academy of Ophthalmology, Research, Paratriathlon, JAMIA, RWD, Millennium, Machine Intelligence Research Institute, CDC, Journal of the American Medical Informatics Association, Patient, EHR, Visual acuity, Comorbidity, SAN, Korea Disease Control and Prevention Agency, Diagnosis, MPH, ICD-9, Health information management, Disease, Medical device, Dietary supplement, Medical imaging, Vaccine

SAN FRANCISCO, May 9, 2023 /PRNewswire/ -- Verana Health®—a digital health company elevating quality in real-world data—today announced its recent ophthalmic research has been published in the peer-reviewed Journal of the American Medical Informatics Association (JAMIA). The study demonstrates how de-identified real-world data (RWD) from electronic health records (EHRs) in medical registries can allow for a deeper understanding of data trends, patterns, or gaps by helping to fill in the missing pieces and providing deeper context.

Key Points: 
  • SAN FRANCISCO, May 9, 2023 /PRNewswire/ -- Verana Health ®—a digital health company elevating quality in real-world data—today announced its recent ophthalmic research has been published in the peer-reviewed Journal of the American Medical Informatics Association (JAMIA).
  • Conducted by a team of Verana Health researchers, the study shows a non-random association between missing EHR data regarding the severity of diabetic retinopathy (DR) in de-identified patients and specific demographic, clinical, and practice-level characteristics.
  • Verana Health elevates data quality, which requires understanding how data is recorded by clinicians in the real world, how diagnosis codes are used to capture disease severity, and completeness of the information.
  • This finding supports the assessment that clinical encounters with unspecified disease severity are associated with less severe DR severity.

Wolters Kluwer Strengthens Clinical Surveillance Portfolio with Sentri7 Sepsis Monitor

Retrieved on: 
Tuesday, November 8, 2022
Medical Devices, Infectious Diseases, Health Technology, Biotechnology, Biometrics, Other Health, Managed Care, Health, General Health, Informatics, American Medical Informatics Association, Patient, Compliance, General manager, Technology, Mortality, Lawyer, EHR, Algorithm, Journal, Doctor of Pharmacy, Journal of the American Medical Informatics Association, Sepsis, Student, Learning, Nursing, Central Arkansas, WKL, Hospital, Wolters, Solution, Research, JAMIA, Risk, Pharmacy, Wolters Kluwer, Medicine, Medical device, Vaccine, Risk management, Health

Wolters Kluwer, Health has expanded the Sentri7 suite of clinical surveillance tools to include Sentri7 Sepsis Monitor empowering hospitals and health systems to identify sepsis earlier and supporting staff in delivering the best care everywhere.

Key Points: 
  • Wolters Kluwer, Health has expanded the Sentri7 suite of clinical surveillance tools to include Sentri7 Sepsis Monitor empowering hospitals and health systems to identify sepsis earlier and supporting staff in delivering the best care everywhere.
  • Sentri7 Sepsis Monitor (formerly known as POC Advisor) leverages clinical natural language processing (cNLP) and advanced algorithms to surveil a hospital's patients 24/7 to identify early signs of sepsis.
  • Now, were delivering this facility-wide surveillance capability for better sepsis performance, said Karen Kobelski , Vice President and General Manager of Clinical Surveillance Compliance & Data Solutions, Wolters Kluwer, Health.
  • Click here to learn more about Sentri7s suite of clinical surveillance solutions, including Sepsis Monitor.

Huma and Tamer bring digital 'hospital at home' platform to the Kingdom of Saudi Arabia to tackle diabetes and cardiovascular disease

Retrieved on: 
Tuesday, May 17, 2022
Diabetes, MHealth, Death, Medicine, BD, Patient, Health, Dialysis, Therapy, CVD, COVID-19, Marketing, Cardiovascular disease, Research, Partnership, Jonathan Obika, Hospital, Technology, NHSX, Attention, Group, LinkedIn, Founder, JAMIA, Glycated hemoglobin, CEO, Health insurance, Pharmaceutical industry, Medical device, Kingdom

The new health programme will begin with support for patients with diabetes and cardiovascular disease.

Key Points: 
  • The new health programme will begin with support for patients with diabetes and cardiovascular disease.
  • Cardiovascular disease (CVD) and diabetes are the biggest cause of premature death in the Kingdom of Saudi Arabia.
  • Patients will now be able to use Huma's award-winning3 'hospital at home' system to give clinicians real-world insightinto their patients' health.
  • Dr Fayad Dandashi, CEO Tamer Healthcare, said: "Tamer is delighted to be able to offer this leading technology.

Huma and Tamer bring digital 'hospital at home' platform to the Kingdom of Saudi Arabia to tackle diabetes and cardiovascular disease

Retrieved on: 
Monday, May 16, 2022
Diabetes, MHealth, Death, Medicine, BD, Patient, Health, Dialysis, Therapy, CVD, COVID-19, Marketing, Cardiovascular disease, Research, Partnership, Jonathan Obika, Hospital, Technology, NHSX, Attention, Group, LinkedIn, Founder, JAMIA, Glycated hemoglobin, CEO, Health insurance, Pharmaceutical industry, Medical device, Kingdom

The new health programme will begin with support for patients with diabetes and cardiovascular disease.

Key Points: 
  • The new health programme will begin with support for patients with diabetes and cardiovascular disease.
  • Cardiovascular disease (CVD) and diabetes are the biggest cause of premature death in the Kingdom of Saudi Arabia.
  • Patients will now be able to use Huma's award-winning3 'hospital at home' system to give clinicians real-world insightinto their patients' health.
  • Dr Fayad Dandashi, CEO Tamer Healthcare, said: "Tamer is delighted to be able to offer this leading technology.

Huma acquires iPLATO Healthcare to advance digital-first delivery of care and remote patient monitoring for NHS patients

Retrieved on: 
Thursday, January 20, 2022
Biomarker, JAMIA, Prescription, Patient, Technology, BD, Degenerative disease, Vital signs, Collection, CEO, Roger Hawkins (drummer), Health care, NHS, Movement, Health, Time, IAPT, Therapy, COVID-19, Depression, Cancer, Pressure, Hospital, MHealth, Medical imaging, Medical device, Pharmaceutical industry

However, remote patient monitoring is still not used widely in primary care.

Key Points: 
  • However, remote patient monitoring is still not used widely in primary care.
  • Dan Vahdat, CEO & Founder of Huma, said: "We are part of the movement using remote patient monitoring and digital biomarkers to transform healthcare.
  • Bringing our patient questionnaires together with Huma's remote patient monitoring capability means that this future is not too far away."
  • We are developing digital biomarkers, predictive algorithms and real-world data from continuous patient monitoring to advance proactive, predictive care.

Sema4 and Mount Sinai use Machine Learning to Improve Postpartum Hemorrhage Risk Prediction

Retrieved on: 
Thursday, November 4, 2021
Phenotype, Icahn School of Medicine at Mount Sinai, MD, Research, SVP, Pre-eclampsia, LinkedIn, Internal bleeding, Obstetrics, Disease, Guideline, Journal of the American Medical Informatics Association, Bleeding, Reproductive health, Risk assessment, Â, Twitter, PPH, Health, Gynaecology, Patient, NASDAQ, Machine learning, YouTube, Vital signs, Risk, American Medical Informatics Association, SMFR, Mount Sinai Health System, Facebook, Death, JAMIA, Mortality, EMR, GLOBE, Mount Sinai, Doctor of Philosophy, Informatics, Journal, AI, Medical device, Medical imaging

Sema4 chose to focus its advanced machine learning methods on PPH as the condition is the leading cause of maternal mortality globally.

Key Points: 
  • Sema4 chose to focus its advanced machine learning methods on PPH as the condition is the leading cause of maternal mortality globally.
  • PPH accounts for around a third of maternal deaths and often occurs in patients with no known risk factors for hemorrhage.
  • The same patient cohort was used in the second study to build, train, and validate a predictive model for PPH risk using advanced machine learning methods.
  • The Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) holds equity in Sema4.Dr.